/ /

  • linkedin
  • Increase Font
  • Sharebar

    Novel dual agonist leads to notable IOP lowering

    Safety, tolerability reasonable for new medication regardless of a.m. or p.m. dosing


    Comparator study

    In the latest research with ONO-9054, a double-masked, parallel group, active comparator study, ONO-9054 was compared against latanoprost using once-daily doses at 10 p.m. for 28 days. All subjects had either ocular hypertension or mild-to-moderate OAG.

    Recent: Glaucoma gene therapy on positive trajectory using this technology

    Investigators measured IOP at 8, 10, and 12 o’clock every day as well as 4 and 8 o’clock at 1 and 29 days. The primary comparison measure was change from baseline to day 29 in terms of mean IOP at all time points. The secondary measure was safety and tolerability, Dr. Miller-Ellis said.

    Investigators found a similar baseline of 24 mm Hg in both treatment groups. Although both ONO-9054 and latanoprost had a significant IOP reduction compared with the untreated baseline, ONO-9054 patients had a more significant drop in IOP, Dr. Miller-Ellis said. This drop was particularly noticeable later in the day.

    Related: Laser therapy addresses bilateral glaucoma in single treatment

    “On day 29, the odds of a more than 25%, 30%, and 35% reduction in IOP were 2.39, 2.37, and 4.85 more with ONO-9054 than the odds for [latanoprost],” Dr. Miller-Ellis said.

    There was also a greater change that ONO-9054 would reduce the IOP by 30% or 40%.

    When investigators selected an IOP goal, such as 17 or 15 mm Hg, such at target was more likely to be reached by the subjects on ONO-9054.

    Safety, tolerability

    Safety and tolerability were similar between the two medications. The only adverse events were ocular in nature and mild or moderate in severity. One case of nonarteritic ischemic optic neuropathy, a serious adverse event, occurred, but it was not related to the study medications.

    More: Pediatric glaucoma's impact beyond clinical effects

    Both medications were associated with hyperemia, which occurred in 12 subjects using ONO-9054 and 5 subjects using latanoprost. The cases of hyperemia all resolved without incident.

    Related: Rocket 2 announces safety results for netarsudil


    Eydie G. Miller-Ellis, MD

    E: [email protected]

    This article was adapted from Dr. Miller-Ellis’ presentation at the 2015 meeting of the American Academy of Ophthalmology. Dr. Miller-Ellis is a consultant for ONO Pharmaceutical.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results